Literature DB >> 12213333

A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells.

Alexis Perez1, Elin S Mier, Nelson Santiago Vispo, Ana Maria Vazquez, Rolando Perez Rodríguez.   

Abstract

P3 (IgM-kappa) is a monoclonal antibody (mAb) reacting with N-glycolyl neuraminic acid (NeuGc)-containing gangliosides and sulfated glycolipids. To explore the nature of the idiotope defined by 1E10, we used a phage-displayed random peptide library. After three rounds of selection, seven different phagotopes were isolated. Noteworthy, all the sequences were found to bear the basic amino acid-rich motifs KPPR (3) or RRPR/K (4). This recursive selection of basic sequences by 1E10 mAb confirmed previous suggestions of the involvement of charged residues in the interaction between gamma-type Ab2 and P3 mAb. The binding of 1E10 to phage peptides representing each group was completely inhibited by P3 mAb. In addition, other Ab2 to P3 were able to recognize these peptides. Thus, phage peptides seem to be mimotopes of the idiotope recognized by anti-idiotypic antibodies in P3. Phage motifs were represented in the lineal sequence of P3's heavy chain H-CDR3 and a 14-mer peptide representing this region was able to specifically inhibit 1E10 binding to P3. Previous studies showed that P3's idiotype was autoimmunogenic and shared by antibodies with different specificities. Now, we demonstrated that P3 mAb is able to activate a network cascade involving autologous anti-idiotypic and anti-anti-idiotypic T cells. Thus, P3's idiotype fulfill the three criteria previously established to define a "regulatory idiotype". Particularly, data presented here revealed the immunodominance of the H-CDR3 of this mAb as a T cell epitope. Thus, H-CDR3 is simultaneously involved in the interaction of P3 mAb with anti-idiotypic B and T cells, behaving as a potential regulatory idiotope.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213333     DOI: 10.1016/s0161-5890(02)00041-x

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

Review 1.  Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.

Authors:  Julien Fleurence; Sophie Fougeray; Meriem Bahri; Denis Cochonneau; Béatrice Clémenceau; François Paris; Andras Heczey; Stéphane Birklé
Journal:  J Immunol Res       Date:  2017-01-05       Impact factor: 4.818

2.  B-CD8+ T Cell Interactions in the Anti-Idiotypic Response against a Self-Antibody.

Authors:  Darel Martínez; Amaury Pupo; Lianet Cabrera; Judith Raymond; Nichol E Holodick; Ana María Hernández
Journal:  J Immunol Res       Date:  2017-04-09       Impact factor: 4.818

Review 3.  The Promise of Anti-idiotype Revisited.

Authors:  Heinz Kohler; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

4.  The promise of the anti-idiotype concept.

Authors:  Thomas Kieber-Emmons; Bejatohlah Monzavi-Karbassi; Anastas Pashov; Somdutta Saha; Ramachandran Murali; Heinz Kohler
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

5.  Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements.

Authors:  Maha Z Ladjemi
Journal:  Front Oncol       Date:  2012-11-06       Impact factor: 6.244

6.  Anti-ganglioside anti-idiotypic vaccination: more than molecular mimicry.

Authors:  Ana M H Vázquez; Nely Rodrèguez-Zhurbenko; Ana M V López
Journal:  Front Oncol       Date:  2012-11-20       Impact factor: 6.244

7.  Potential of peptides as inhibitors and mimotopes: selection of carbohydrate-mimetic peptides from phage display libraries.

Authors:  Teruhiko Matsubara
Journal:  J Nucleic Acids       Date:  2012-10-10

8.  P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties.

Authors:  Darel Martínez; Nely Rodríguez; Tania Griñán; Teresa Rondón; Ana María Vázquez; Rolando Pérez; Ana María Hernández
Journal:  Front Immunol       Date:  2012-04-26       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.